Akeso Biopharma is a technology company.
康方生物由经验丰富的国际化团队创建，聚焦肿瘤、自身免疫、炎症、代谢疾病等重大疾病领域，专注于全球未被满足的临床需求，打造了独有的端对端康方全方位新药研究开发平台（ACE Platform）。
Akeso Biopharma has raised $150.0M across 1 funding round.
Akeso Biopharma has raised $150.0M in total across 1 funding round.
Akeso Biopharma is a commercial-stage biopharmaceutical company specializing in antibody therapeutics for oncology and immunology.[1][2] It develops innovative drugs and biologics through rigorous clinical trials, targeting regulatory approvals from bodies like the U.S. FDA and China's NMPA to deliver new therapies to patients.[1] Akeso serves patients with cancers and immune disorders, addressing unmet needs in treatment efficacy and accessibility by advancing investigational medicines toward market approval, while prioritizing clinical trial participation over expanded access programs.[1][2]
The company demonstrates growth momentum as a commercial-stage player actively seeking U.S. and EU partnerships for development and commercialization, signaling expansion beyond its Zhongshan, Guangdong base in China.[2]
Akeso Biopharma emerged as a biotech focused on R&D in therapeutic antibodies, though specific founding details like year or key founders are not detailed in available sources.[1][2] Its backstory centers on a commitment to clinical innovation, conducting trials to gather safety and efficacy data for oncology and immunology drugs, with a pivotal emphasis on securing approvals from major regulators like FDA and NMPA.[1] Early traction likely built through this pipeline, evolving into a commercial-stage entity now exhibiting at global events like BIO International Convention 2025 and pursuing international partnerships.[2]
Akeso rides the global wave of antibody therapeutics in oncology and immunology, where biologics address complex diseases amid rising demand for targeted, less toxic treatments.[2] Timing aligns with accelerating FDA/NMPA approvals for Chinese biopharmas, fueled by market forces like aging populations, immunotherapy breakthroughs, and cross-border partnerships amid U.S.-China biotech collaborations.[1][2] It influences the ecosystem by exemplifying China's outbound biotech push, enhancing competition and innovation in antibody R&D while bridging Eastern manufacturing scale with Western commercialization needs.[2]
Akeso is poised for pipeline milestones, with potential FDA/NMPA nods unlocking U.S./EU markets via partnerships.[1][2] Trends like AI-accelerated antibody design and combo therapies will shape its trajectory, amplifying growth if trials yield strong data. Its influence may evolve from regional player to global contender, tying back to its core mission of innovative patient therapies through disciplined clinical advancement.[1][2]
Akeso Biopharma has raised $150.0M in total across 1 funding round.
Akeso Biopharma's investors include OrbiMed.
Akeso Biopharma has raised $150.0M across 1 funding round. Most recently, it raised $150.0M Series D in November 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2019 | $150.0M Series D | OrbiMed |